NO955352D0 - Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse - Google Patents

Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse

Info

Publication number
NO955352D0
NO955352D0 NO955352A NO955352A NO955352D0 NO 955352 D0 NO955352 D0 NO 955352D0 NO 955352 A NO955352 A NO 955352A NO 955352 A NO955352 A NO 955352A NO 955352 D0 NO955352 D0 NO 955352D0
Authority
NO
Norway
Prior art keywords
preparation
pct
acid ester
phosphoric acid
methyl phosphoric
Prior art date
Application number
NO955352A
Other languages
English (en)
Other versions
NO955352L (no
NO319860B1 (no
Inventor
Eugen Uhlmann
Chris Meier
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO955352D0 publication Critical patent/NO955352D0/no
Publication of NO955352L publication Critical patent/NO955352L/no
Publication of NO319860B1 publication Critical patent/NO319860B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO19955352A 1993-07-01 1995-12-29 Metylfosfonsyre-ester, fremgangsmate for fremstilling, legemiddel samt anvendelse NO319860B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4321946A DE4321946A1 (de) 1993-07-01 1993-07-01 Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
PCT/EP1994/002121 WO1995001363A1 (de) 1993-07-01 1994-06-29 Methylphosphonsäureester, verfahren zu deren herstellung und deren verwendung

Publications (3)

Publication Number Publication Date
NO955352D0 true NO955352D0 (no) 1995-12-29
NO955352L NO955352L (no) 1996-02-14
NO319860B1 NO319860B1 (no) 2005-09-26

Family

ID=6491730

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19955352A NO319860B1 (no) 1993-07-01 1995-12-29 Metylfosfonsyre-ester, fremgangsmate for fremstilling, legemiddel samt anvendelse

Country Status (13)

Country Link
US (1) US6028182A (no)
EP (1) EP0707591B1 (no)
JP (1) JP3831407B2 (no)
AT (1) ATE206130T1 (no)
AU (1) AU698928B2 (no)
CA (1) CA2165971C (no)
DE (2) DE4321946A1 (no)
DK (1) DK0707591T3 (no)
ES (1) ES2165391T3 (no)
FI (1) FI115399B (no)
NO (1) NO319860B1 (no)
PT (1) PT707591E (no)
WO (1) WO1995001363A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
ES2165446T3 (es) * 1995-03-13 2002-03-16 Aventis Pharma Gmbh Fosfonomonoester-acidos nucleicos, procedimiento para su preparacion y su utilizacion.
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
ATE342911T1 (de) * 1996-12-24 2006-11-15 Sirna Therapeutics Inc Synthese von nukleosiden und polynukleotiden
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US20020119178A1 (en) * 2001-02-23 2002-08-29 Luc Levesque Drug eluting device for treating vascular diseases
GB0110732D0 (en) * 2001-05-02 2001-06-27 Psl Technology Ltd Apparatus and method
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
ATE544466T1 (de) 2002-10-29 2012-02-15 Coley Pharm Group Inc Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
WO2005097993A2 (en) 2004-02-19 2005-10-20 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
NZ553244A (en) 2004-07-18 2009-10-30 Csl Ltd Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
ES2553284T5 (es) 2006-02-15 2021-08-31 Rechtsanwalt Thomas Beck Composiciones y procedimientos para formulaciones de oligonucleótidos
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
KR20100010509A (ko) * 2007-05-17 2010-02-01 콜레이 파마시티컬 그룹, 인코포레이티드 면역자극 효과를 갖는 ａ 클래스 올리고뉴클레오타이드
KR20100068422A (ko) 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
EP2306986B1 (en) 2008-06-26 2018-03-21 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
EP2376108B1 (en) 2008-12-09 2017-02-22 Pfizer Vaccines LLC IgE CH3 PEPTIDE VACCINE
PE20110998A1 (es) 2008-12-09 2012-02-10 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores
PE20120817A1 (es) 2009-07-30 2012-07-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos
US10456463B2 (en) 2010-05-28 2019-10-29 Zoetis Belgium S.A Vaccines comprising cholesterol and CpG as sole adjuvant-carrier molecules
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
MX359257B (es) 2012-05-04 2018-09-19 Pfizer Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
WO2016109310A1 (en) 2014-12-31 2016-07-07 Checkmate Pharmaceuticals, Llc Combination tumor immunotherapy
JP7511478B2 (ja) 2018-04-09 2024-07-05 チェックメイト ファーマシューティカルズ ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
WO2024127215A2 (en) 2022-12-13 2024-06-20 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010140A1 (en) * 1991-11-21 1993-05-27 Pharmagenics, Inc. Oligonucleotides having modified anionic moieties

Also Published As

Publication number Publication date
DE4321946A1 (de) 1995-01-12
NO955352L (no) 1996-02-14
JPH08512039A (ja) 1996-12-17
FI956341A0 (fi) 1995-12-29
JP3831407B2 (ja) 2006-10-11
ES2165391T3 (es) 2002-03-16
US6028182A (en) 2000-02-22
WO1995001363A1 (de) 1995-01-12
EP0707591A1 (de) 1996-04-24
CA2165971A1 (en) 1995-01-12
PT707591E (pt) 2002-03-28
EP0707591B1 (de) 2001-09-26
FI956341A (fi) 1996-02-19
CA2165971C (en) 2006-05-30
FI115399B (fi) 2005-04-29
ATE206130T1 (de) 2001-10-15
DK0707591T3 (da) 2002-01-21
NO319860B1 (no) 2005-09-26
AU698928B2 (en) 1998-11-12
AU7073594A (en) 1995-01-24
DE59409880D1 (de) 2001-10-31

Similar Documents

Publication Publication Date Title
NO955352D0 (no) Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse
HUT77925A (hu) Dihidrobenzofuránok, azokat tartalmazó gyógyászati készítmények és eljárás előállításukra
AU4115396A (en) 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
HUT76548A (en) Aryl-sulfonamido-hydroxamic acids of matrix-metalloproteinase-inhibiting activity
EP0948327A4 (en) ANTIDIABETIC AGENTS
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
PL300328A1 (en) Substituted cyclohexane derivatives for treating diseases
WO2001091738A3 (en) Naaladase inhibitors for treating amyotrophic lateral sclerosis
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
CA2094806A1 (en) Aminosulfonyl urea acat inhibitors
BR9408244A (pt) Derivados de azabiciclo[3.2.0]heptano N-substituídos
AU686197B2 (en) Use of coumarins and carbostyrils as PLA2-inhibitors, new coumarins and carbostyrils, process for preparing the same and medicaments
ATE123773T1 (de) 1,3,5-triazin-2,4,6-tris- alkylaminocarbonsäureaminoester, diese enthaltende biozide mittel sowie verfahren zu ihrer herstellung.
TW261614B (no)
ATE163402T1 (de) Substituierte ortho- ethenylphenylessigsäurederivate
EP0653206A4 (en) ANTI-HIV ACTIVE SUBSTANCE.
PL355763A1 (en) Novel derivatives of 3-imino-1,2-dithioles, method for producing them and pharmaceutical compositions containing the same